CD42b Antibody - #DF8519

(2)   (4)  
製品: CD42b Antibody
カタログ: DF8519
タンパク質の説明: Rabbit polyclonal antibody to CD42b
アプリケーション: WB IHC
Cited expt.: WB
反応性: Human, Mouse
予測: Bovine, Rabbit, Dog
分子量: 70kD, 100~140kD; 72kD(Calculated).
ユニプロット: P07359
RRID: AB_2841724

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MS Report
HPLC Report
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:1000-3000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse
予測:
Bovine(83%), Rabbit(83%), Dog(92%)
クローナリティ:
Polyclonal
特異性:
CD42b Antibody detects endogenous levels of total CD42b.
RRID:
AB_2841724
引用形式: Affinity Biosciences Cat# DF8519, RRID:AB_2841724.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

Antigen CD42b alpha; BDPLT1; BDPLT3; BSS; CD 42b; CD42b alpha; CD42B; CD42b antigen; DBPLT3; GLYCOCALICIN; Glycoprotein Ib (platelet) alpha polypeptide; Glycoprotein Ibalpha; GP Ib alpha; GP1B; GP1BA; GPIb alpha; GPIbA; MGC34595; Platelet glycoprotein Ib alpha chain; Platelet glycoprotein Ib alpha polypeptide; Platelet membrane glycoprotein 1b alpha subunit; VWDP;

免疫原

免疫原:

A synthesized peptide derived from human CD42b, corresponding to a region within C-terminal amino acids.

Uniprot:

P07359(GP1BA_HUMAN) >>Visit HPA database.

遺伝子(ID):
GP1BA(2811)
タンパク質配列:
MPLLLLLLLLPSPLHPHPICEVSKVASHLEVNCDKRNLTALPPDLPKDTTILHLSENLLYTFSLATLMPYTRLTQLNLDRCELTKLQVDGTLPVLGTLDLSHNQLQSLPLLGQTLPALTVLDVSFNRLTSLPLGALRGLGELQELYLKGNELKTLPPGLLTPTPKLEKLSLANNNLTELPAGLLNGLENLDTLLLQENSLYTIPKGFFGSHLLPFAFLHGNPWLCNCEILYFRRWLQDNAENVYVWKQGVDVKAMTSNVASVQCDNSDKFPVYKYPGKGCPTLGDEGDTDLYDYYPEEDTEGDKVRATRTVVKFPTKAHTTPWGLFYSWSTASLDSQMPSSLHPTQESTKEQTTFPPRWTPNFTLHMESITFSKTPKSTTEPTPSPTTSEPVPEPAPNMTTLEPTPSPTTPEPTSEPAPSPTTPEPTSEPAPSPTTPEPTSEPAPSPTTPEPTPIPTIATSPTILVSATSLITPKSTFLTTTKPVSLLESTKKTIPELDQPPKLRGVLQGHLESSRNDPFLHPDFCCLLPLGFYVLGLFWLLFASVVLILLLSWVGHVKPQALDSGQGAALTTATQTTHLELQRGRQVTVPRAWLLFLRGSLPTFRSSLFLWVRPNGRVGPLVAGRRPSALSQGRGQDLLSTVSIRYSGHSL

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Dog
92
Bovine
83
Rabbit
83
Pig
0
Horse
0
Sheep
0
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

研究背景

機能:

GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium.

PTMs:

Glycocalicin is the product of a proteolytic cleavage/shedding, catalyzed by ADAM17, which releases most of the extracellular domain. Binding sites for vWF and thrombin are in this part of the protein.

細胞の位置付け:

Membrane>Single-pass type I membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location

研究領域

· Environmental Information Processing > Signaling molecules and interaction > ECM-receptor interaction.   (View pathway)

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

· Organismal Systems > Immune system > Hematopoietic cell lineage.   (View pathway)

参考文献

1). Engineered exosome nanovesicles for delivery of antibodies to treat inflammatory bowel disease. Nature Communications, 2026 (PubMed: 41688436) [IF=15.7]

Application: WB    Species: Mouse    Sample: exosomes

Fig. 2 | Preparation and characterization of PrEXO-a23. (e) Western blot analysis of protein markers in rEXO, PMV, a23, and PrEXO-a23.
2). Curcumin-loaded milk-derived sEVs fused with platelet membrane attenuate endothelial senescence and promote spinal cord injury recovery in diabetic mice. Materials today. Bio, 2025 (PubMed: 40688662) [IF=8.7]

Application: WB    Species: Mouse    Sample:

Fig. 4. Preparation and characterization of PM-sEVs. (A) Typical TEM images of sEVs and PM-sEVs. Both sEVs and PM-sEVs exhibited characteristic cup-shaped morphology. Scale bar = 100 nm. (B, C) Size distribution of sEVs and PM-sEVs by NTA analysis. sEVs and PM-sEVs exhibited similar size distributions. (D) Typical images of PM-sEVs, DiO-labeled sEVs, DiL-labeled PM. Scale bar = 20 μm. The co-localization (yellow signals) of DiO (sEVs) and DiL (PM) fluorescence indicates successful fusion. (E) Analysis of Tsg-101, Alix, CD9, GPIbα, Integrin β1 and Integrin α2 expression of sEVs, PM-sEVs and PM by WB. Note: (1) sEVs markers (Tsg101, Alix, CD9) were enriched in both sEVs and PM-sEVs. (2) PM markers (GPIbα, Integrin β1, Integrin α2) were expressed in PM and PM-sEVs, but absent (or very low) in sEVs, confirming the incorporation of PM proteins onto PM-sEVs. (F) Typical images of DiO-labeled sEVs and PM-sEVs incubated with HUVECs. Scale bar = 20 μm. The significantly enhanced cellular uptake of DiO-PM-sEVs compared to that of DiO-sEVs demonstrated the improved targeting efficiency mediated by the PM coating. (G) IVIS images showing the distribution of sEVs, PM-sEVs and PM in the spinal cord. The fluorescence intensity was higher at the SCI site in the PM-sEVs group than in the sEVs group. (H) Cur release kinetics. The sustained release kinetics of Cur from PM-sEVs-Cur and sEVs-Cur were compared to the faster release of Cur alone. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.